These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18662137)

  • 21. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon.
    Burda ST; Viswanath R; Zhao J; Kinge T; Anyangwe C; Tinyami ET; Haldar B; Powell RL; Jarido V; Hewlett IK; Nyambi PN
    J Med Virol; 2010 Feb; 82(2):187-96. PubMed ID: 20029816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
    Andreatta K; Kulkarni R; Abram ME; Nguyen T; Cao H; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):519-26. PubMed ID: 25559592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.
    Rousseau MN; Vergne L; Montes B; Peeters M; Reynes J; Delaporte E; Segondy M
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):36-43. PubMed ID: 11176267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
    Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
    HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.
    Mackie NE; Dunn DT; Dolling D; Garvey L; Harrison L; Fearnhill E; Tilston P; Sabin C; Geretti AM; ;
    AIDS; 2013 Sep; 27(14):2245-53. PubMed ID: 24157905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.
    Arnedo-Valero M; Garcia F; Gil C; Guila T; Fumero E; Castro P; Blanco JL; Miró JM; Pumarola T; Gatell JM
    Clin Infect Dis; 2005 Sep; 41(6):883-90. PubMed ID: 16107990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.
    Pillay V; Pillay C; Kantor R; Venter F; Levin L; Morris L
    AIDS Res Hum Retroviruses; 2008 Nov; 24(11):1449-54. PubMed ID: 19000027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.
    Tambuyzer L; Vingerhoets J; Azijn H; Daems B; Nijs S; de Béthune MP; Picchio G
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1197-205. PubMed ID: 20854144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.
    Theys K; Snoeck J; Vercauteren J; Abecasis AB; Vandamme AM; Camacho RJ;
    J Antimicrob Chemother; 2013 Feb; 68(2):419-23. PubMed ID: 23027713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.
    ;
    Clin Infect Dis; 2010 May; 50(9):1275-85. PubMed ID: 20353366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.
    Seu L; Mulenga LB; Siwingwa M; Sikazwe I; Lambwe N; Guffey MB; Chi BH
    J Med Virol; 2015 Jul; 87(7):1149-57. PubMed ID: 25754408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.
    Dagnra AY; Vidal N; Mensah A; Patassi A; Aho K; Salou M; Monleau M; Prince-David M; Singo A; Pitche P; Delaporte E; Peeters M
    J Int AIDS Soc; 2011 Jun; 14():30. PubMed ID: 21663632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.
    Spertilli Raffaelli C; Rossetti B; Paglicci L; Colafigli M; Punzi G; Borghi V; Pecorari M; Santoro MM; Penco G; Antinori A; Zazzi M; De Luca A; Zanelli G
    J Antimicrob Chemother; 2018 Sep; 73(9):2480-2484. PubMed ID: 29945251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.